ROSE Diagnostics closes seed round with $1M Reg D financing

Carlsbad, California – June 27th 2024

ROSE Diagnostics, an innovative leader in rapid cancer diagnostics, today announced the successful completion of its seed round, securing $1 million through a Reg D financing. This milestone marks a significant step forward in the company's mission to commercialize its impactful line of point-of-care products for cancer biopsy verifications.

The private, Regulation D offering attracted a diverse group of investors including industry veterans and entrepreneurs with successful exits, signaling broad interest and confidence in ROSE Diagnostics' vision. With the successful close of the seed round, the company is well-positioned to launch their clinical studies in early 2025.

The funds raised will be used to accelerate ROSE Diagnostics' growth, including investments in product development and the launch of their clinical trials. The company has already achieved great strides in improving their verifi LUNG prototype, positioning itself for FDA approval and commercialization in the future.

For further inquiries, please contact: info@rose-dx.com